News
Resources
Blog
Sites
Tom Wilbur is Senior Director of Public Affairs at PhRMA focused on opinion research, message development and political communications. Prior to joining PhRMA in 2019, Tom worked on Capitol Hill and on political campaigns for eight years, most recently responsible for communications and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the office enjoys spending time with friends and family, reading, running, hiking, and golfing.
Recent Posts
In their own words: Insured Americans struggle to navigate complex coverage
By Tom Wilbur | October 26, 2022
A survey of more than 5,000 Americans conducted with Ipsos found that nearly 40% of insured Americans struggle to understand what their health insurance covers.
Read More
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
By Tom Wilbur | July 12, 2022
As policymakers race to pass government price setting policies, it’s important to examine true public sentiment around such proposals. Voters have made clear that they do not support policies such as...
Read More
5 public opinion polling trends to watch
By Tom Wilbur | April 22, 2022
Today, we’re taking a closer look at Americans’ leading concerns and what issues they want policymakers to prioritize.
Read More
Legislation threatens patent protections and future innovation
By Tom Wilbur | January 12, 2022
Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant more...
Read More
Three things to know about so-called Medicare negotiation polling
By Tom Wilbur | November 18, 2021
As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to...
Read More
Recent polling misrepresents public support for Medicare “negotiation”
By Tom Wilbur | August 31, 2021
Proponents of government price setting often misrepresent voters’ opinions on support for allowing the federal government to “negotiate” drug prices. This includes recent polling from advocacy firms...
Read More
Myth vs. fact: Polling and Medicare “negotiation”
By Tom Wilbur | August 12, 2021
As some in Washington consider legislation related to prescription medicines and how to best help Americans manage health care costs, government “negotiation” of prescription medicines within...
Read More
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
By Tom Wilbur | July 2, 2021
As we head into the Fourth of July weekend, Americans are reemerging from the COVID-19 pandemic with heightened hopes and confidence in a strong U.S. recovery. The COVID-19 vaccines have been...
Read More
Health care costs and affordability remain a major challenge for most Americans, even among those with insurance. According to a March Gallup poll, nearly one-in-five (18%) U.S. adults report that if...
Read More
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
By Tom Wilbur | March 11, 2021
On January 19, 2021 – the last full day of the Trump administration – CMS released a Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This model would provide...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
